December 22, 2015
1 min read

METIV-HCC tivantinib phase 3 trial completes enrollment for HCC

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

ArQule, Inc. and Daiichi Sankyo, Inc. announced that enrollment of the phase 3 METIV-HCC clinical trial investigating tivantinib for the treatment of hepatocellular carcinoma is complete.

METIV-HCC is a double-blind, placebo controlled trial and will include at least 300 patients with HCC and MET-high tumors randomly assigned a treatment regimen of tivantinib (ARQ 197, ArQule) — a selective inhibitor of the c-Met receptor, tyrosine kinase — or to supportive care for comparison. The primary endpoint of the trial is overall survival.

“We are pleased to have fully accrued the METIV-HCC trial prior to year-end,” Brian

Schwartz, MD, head of research and development and chief medical officer at ArQule Inc., said in the release. “HCC is a disease with high unmet need and with no approved therapy for second-line treatment. It has been very encouraging to see a growing body of evidence supporting the phase 3 clinical evaluation of tivantinib in MET-high populations through a recent presentation at the International Liver Cancer Association conference.”

The trial is currently being conducted in Western countries.

Disclosure: Schwartz is employed by ArQule, Inc.